SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 9, 2000
CARTER-WALLACE, INC.
(Exact name of registrant as specified in its charter)
1-5910
(Commission File Number)
Delaware 13-4986583
(State or other jurisdiction (I.R.S. Employer
of incorporation) identification number)
l345 Avenue of the Americas
New York, New York 10105
(Address of principa (Zip Code)
executive offices)
Registrant's telephone number, including area code 212-339-5000
(Former name or former address, if changed since last report)
Item 5. Other Events.
On August 9, 2000, Carter-Wallace, Inc. issued a press release reporting
that the United States Court of Appeals for the Second Circuit affirmed a lower
court dismissal of all shareholder Security Act claims against the registrant
relating to Felbatol, the registrant's anti-epilepsy drug. A copy of such
press release is attached hereto as Exhibit (99) and incorporated herein by
reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits:
(99) Press release issued by Carter-Wallace, Inc. on August 9, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CARTER-WALLACE, INC.
(Registrant)
August 10, 2000 /s/ Ralph Levine
Name: Ralph Levine
Title: President and Chief Operating Officer
For Immediate Release
APPEALS COURT AFFIRMS DISMISSAL OF SECURITIES CLASS ACTION
AGAINST CARTER-WALLACE
NEW YORK - August 9, 2000 - Carter-Wallace, Inc. (NYSE - CAR) announced today
that the United States Court of Appeals for the Second Circuit affirmed a lower
court dismissal of all shareholder Security Act claims against the company
relating to Felbatol, the company's anti-epilepsy drug.
Two consolidated federal securities class action suits filed in 1994 by
stockholders against the company and certain of its present and former officers
in the United States District Court, Southern District of New York, alleged
that certain statements made by the company with respect to the safety and
anticipated future sales of Felbatol were false and misleading.
In upholding the dismissal of these claims, the appellate court stated that
Carter-Wallace had "acted reasonably" in alerting the medical profession of
adverse side effects once a linkage was established with Felbatol and that the
plaintiff shareholders had "failed adequately to plead reckless behavior on
Carter-Wallace's part."
Ralph Levine, President and Chief Operating Officer of Carter-Wallace, said
"we are gratified that this long-pending litigation has finally come to an end."
Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that forward-looking statements involve risks and uncertainties which
may affect the company's business and prospects, and cause results to differ
materially from those set forth in the forward-looking statements. These risks
include, among other things, the risk that the shareholder plaintiffs may
seek re-hearing of the appellate decision or appeal to the United States Supreme
Court. In addition to these factors, the economic, competitive, governmental,
technological and other factors identified in the company's filings with the
Securities and Exchange Commission could affect the forward-looking statements
contained in this release.
[Text of Press Release]
